Traditionally, the use of AC is based upon clinicopathological characteristics, including patient age, menopausal status, tumor hormonal status, human epidermal growth factor (HER2) status, Ki67 proliferation index, and tumor, nodes, and metastases (TNM) stage [7]. This evidence concerns the gene ERBB2 and neoplasm.